• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

T2DM: Intensifying Rx When Diet, Lifestyle and OADs Aren't Enough


A how-to overview of how to advance therapy for hyperglycemia and ASCVD risk factors in patients with T2DM.

In this portion of our Type 2 Diabetes: Back to Basics Special Report, author Dr Susan Williams summarizes the essential principles of T2DM management when diet and lifestyle changes and the addition of 1 or more antihyperglycemic agents have not lowered A1c to the goal set for an individual patient. Included are sections on initiating and intensifying insulin and on precautions to help avoid hypoglycemia.These slides are based on-and incorporate-slides from the AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm 2017 which is available on the AACE website. The algorithm spends equal time on management of T2DM comorbidities/ASCVD risk factors. The presentation summarizes the AACE/ACE 2017 Consensus Statement on comprehensive T2DM management.PLEASE NOTE: TO ENLARGE TABLES ON SLIDES 6, 8, 10, 12, 14, 16, AND 27, PLEASE CLICK ON THE LINK PROVIDED IN THE CAPTION; see example below.[[{"type":"media","view_mode":"media_crop","fid":"59882","attributes":{"alt":"","class":"media-image","height":"289","id":"media_crop_9937304821384","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"7543","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","title":" ","typeof":"foaf:Image","width":"379"}}]]

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2024 MJH Life Sciences

All rights reserved.